| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Benjamin Burnett maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight and raises the price...
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that it has commenced an u...
Wells Fargo analyst Benjamin Burnett maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight and lowers the price...
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results for the ...
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.41) per share which missed the analyst consensus estima...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight r...